$25.76
7.04% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US00847X1046
Symbol
AGIO
Sector
Industry

Agios Pharmaceuticals, Inc. Stock price

$25.76
-7.63 22.85% 1M
-15.57 37.66% 6M
-7.10 21.61% YTD
-2.16 7.74% 1Y
-5.66 18.01% 3Y
-13.74 34.78% 5Y
-68.57 72.69% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-1.95 7.04%
ISIN
US00847X1046
Symbol
AGIO
Sector
Industry

Key metrics

Market capitalization $1.48b
Enterprise Value $639.23m
P/E (TTM) P/E ratio 2.26
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 17.51
P/S ratio (TTM) P/S ratio 40.44
P/B ratio (TTM) P/B ratio 0.96
Revenue growth (TTM) Revenue growth 36.07%
Revenue (TTM) Revenue $36.50m
EBIT (operating result TTM) EBIT $-425.74m
Free Cash Flow (TTM) Free Cash Flow $-391.53m
Cash position $893.71m
EPS (TTM) EPS $11.40
P/E forward negative
P/S forward 28.86
EV/Sales forward 12.50
Short interest 6.03%
Show more

Is Agios Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Agios Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Agios Pharmaceuticals, Inc. forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Agios Pharmaceuticals, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Agios Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
37 37
36% 36%
100%
- Direct Costs 9.82 9.82
34% 34%
27%
27 27
121% 121%
73%
- Selling and Administrative Expenses 151 151
47% 47%
414%
- Research and Development Expense 296 296
2% 2%
810%
-420 -420
11% 11%
-1,151%
- Depreciation and Amortization 5.65 5.65
52% 52%
15%
EBIT (Operating Income) EBIT -426 -426
9% 9%
-1,166%
Net Profit 674 674
291% 291%
1,846%

In millions USD.

Don't miss a Thing! We will send you all news about Agios Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Agios Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company's 2023 Stock Incentive Plan to its newly appointed Chief Corporate Development & Strategy Officer, Krishnan Viswana...
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the following conferences: Leerink Global Healthcare Conference 2025: Fireside chat on Tuesday, March 11, 2025, at 10:50 a.m.
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 10:30 a.m. ET.
More Agios Pharmaceuticals, Inc. News

Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Head office United States
CEO Brian Goff
Employees 488
Founded 2007
Website www.agios.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today